ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 1

Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

, , ,

Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
    EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
    EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
    EP. 4: Examining 3-Year Update Data from the CASPIAN Trial
    EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC
    EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
    EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial
    EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
    EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
    EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
    EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
    EP. 12: Examining Key Data from DAREON-8
    EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer
    1. Briefly explore the current landscape of first-line treatment for limited-stage small cell lung cancer:
      1. What clinical factors influence or impact the initial diagnostic workup and management of patients with LS-SCLC?
      2. To what degree is a multidisciplinary team approach adopted when developing a treatment plan for patients with SCLC?
      3. With respect to limited-stage disease, which patients are most likely to benefit from surgery and does lobectomy remain the preferred procedure for stageI-IIA (T1-2,N0,M0) disease?
      4. To what degree does pathologic mediastinal lymph node stage influence your treatment path?
    2. Under what circumstances would surgery versus RT be a preferred approach for a patient with stage I-IIA SCLC?
    x